| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| Fas Ligand | Human Fas Ligand / TNFSF6 Protein, His Tag, premium grade (Mass Spec verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $485.00 50ug | ||
| Fas Ligand | Cynomolgus / Rhesus macaque Fas Ligand / TNFSF6 Protein, His Tag, premium grade | Cynomolgus / Rhesus macaque | HEK293 | ![]() | MALSSDS-PAGE | $420.00 50ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Asunercept | CAN-008; APG-101 | Phase 2 Clinical | Apogenix Gmbh | Coronavirus Disease 2019 (COVID-19); Eye Diseases; Glioblastoma; Hematologic Neoplasms; Myelodysplastic Syndromes; Skin Diseases; Solid tumours | Details |
| Xelafaslatide | ONL-1204 | Phase 2 Clinical | Onl Therapeutics | Geographic Atrophy; Glaucoma, Open-Angle; Macular Degeneration; Retinal Detachment | Details |
| M3T01 | M3T01 | Phase 1 Clinical | Providence Health & Services | Solid tumours | Details |